Compare ZJYL & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZJYL | LEXX |
|---|---|---|
| Founded | 2006 | 2004 |
| Country | China | Canada |
| Employees | N/A | 7 |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.9M | 16.2M |
| IPO Year | 2020 | N/A |
| Metric | ZJYL | LEXX |
|---|---|---|
| Price | $2.26 | $0.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 13.5K | ★ 186.8K |
| Earning Date | 08-20-2025 | 04-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $601.47 |
| P/E Ratio | $18.40 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.10 | $0.46 |
| 52 Week High | $2.86 | $1.55 |
| Indicator | ZJYL | LEXX |
|---|---|---|
| Relative Strength Index (RSI) | 65.71 | 47.95 |
| Support Level | $0.19 | $0.81 |
| Resistance Level | $2.45 | $1.05 |
| Average True Range (ATR) | 0.19 | 0.08 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 77.55 | 10.12 |
Jin Medical International Ltd, along with its subsidiaries, mainly offers rehabilitation equipment. It is engaged in the design, development, manufacturing, and sales of wheelchairs and other assistive living aid products for use by people with disabilities or impaired mobility. The group's product offering includes wheelchairs and wheelchair components, oxygen concentrators, bathing machines, respiratory and walking aids, oxygen chambers, beauty instruments, and nano products, among others. Wheelchairs are currently its key revenue-generating product. The products are sold to dealers in Japan and China, and to some extent to dealers located in the United States, Canada, Australia, Korea, Israel, Singapore, and other regions. Geographically, the group generates maximum revenue from Japan.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.